An observational study in Obesity, Obesity, Morbid and Obesity Associated Disorder, sponsored by Christopher C. Thompson, MD, MSc. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-02.
Sponsored by Christopher C. Thompson, MD, MSc · Observational
This is a prospective collection of data from adult patients who have had an endoscopic metabolic and bariatric endoscopy procedure (EMBT) for primary or revision surgical procedures for obesity.
The Investigators will be collecting data on bariatric patients post-bariatric surgery, post-endoscopic revision of bariatric surgical complications and post-endoscopic metabolic and bariatric therapies (including but not limited to roux-en-y gastric bypass, sleeve gastrectomy, laparoscopic adjustable gastric banding, gastroplasty with endoscopic myotomy (GEM), endoscopic sleeve gastroplasty (ESG), transoral outlet reduction (TORe), primary obesity surgery endoluminal (POSE), restorative obesity surgery endoluminal (ROSE), intragastric balloons (IGB), aspiration therapy and pylorus sparing antral myotomy) to review demographics, adverse events, medications, radiology, procedure time, cost, comorbidity resolution and resource utilization.
11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.
This study's planned enrollment of 5,000 is above the median of 114 across 2,154 observational studies indexed under Obesity.
Browse Obesity studies →Christopher C. Thompson, MD, MSc is the lead sponsor of 6 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult patients registered with Mass General Brigham affiliate facilities who have undergone an endoscopic primary obesity procedure, an endoscopic bariatric revision procedure, or a bariatric surgical procedure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Primary endoscopic procedures for treatment of obesity.
Procedure: Primary Obesity Endoscopic Procedures · Device: Endoscopic Sleeve Gastroplasty, Trans-oral Outlet Reduction · Device: Intragastric Balloon · Device: Primary obesity surgery endoluminal, Restorative obesity surgery endoluminal · Device: Argon Plasma Coagulation, Gastroplasty with Endoscopic Myotomy, Bariatric Endoscopic Antral Myotomy, Pylorus Sparing Antral Myotomy · Device: Aspiration Therapy
Endoscopic revision of post-bariatric surgical complications.
Procedure: Endoscopic Revision of Bariatric Surgical Procedures · Device: Endoscopic Sleeve Gastroplasty, Trans-oral Outlet Reduction · Device: Primary obesity surgery endoluminal, Restorative obesity surgery endoluminal · Device: Argon Plasma Coagulation, Gastroplasty with Endoscopic Myotomy, Bariatric Endoscopic Antral Myotomy, Pylorus Sparing Antral Myotomy
Bariatric surgical procedures.
Procedure: Bariatric Surgery Procedures
Any primary endoscopic procedure for treatment of obesity including endoscopic sleeve gastroplasty (ESG), intragastric balloons (IGB), Aspiration therapy, pylorus sparing antral myotomy (PSAM), primary obesity surgery endoluminal (POSE), gastroplasty with endoscopic myotomy (GEM).
Also known as: ESG, Aspiration Therapy, IGB, POSE, GEM, PSAM, BEAM, EMBTs
Any endoscopic revision procedure in a post-bariatric surgical patient, including transoral outlet reduction (TORe), restorative obesity surgery endoluminal (ROSE), argon plasma coagulation of the outlet (APC), endoscopic suturing.
Also known as: TORe, ROSE, APC
Any bariatric surgical procedure including Roux-en-Y gastric bypass (RYGB), laparoscopic sleeve gastroplasty (LSG), laparoscopic adjustable gastric banding (LAGB)
Also known as: RYGB, LSG, LAGB
Any endoscopic procedure using an endoscopic suturing device for primary obesity treatment or revision of post bariatric complications.
Also known as: ESG, TORe
An endoscopic bariatric procedure involving the placement of an intragastric balloon.
Also known as: IGB
Any endoscopic procedure using an endoscopic plicating device for primary obesity treatment or revision of post bariatric complications.
Also known as: POSE, ROSE
Electrosurgical interventions for obesity. Use of electrosurgical devices, such as electrocautery for the primary treatment of obesity or obesity related complications.
Also known as: APC, GEM, BEAM, PSAM
Placement of an aspiration therapy device for the treatment of obesity.
Also known as: Aspire
Change in weight from pre-procedure to 10 years
%TBWL
Time frame: Baseline, 3 months, 6 months, 9 months, 12 months, years 1-10.
Change in hypertension from pre-procedure to 10 years using blood pressure measurements
Change of hypertension status by comparing blood pressure measurements (systolic/diastolic mmHg) from baseline.
Time frame: Baseline, 3 months, 6 months, 9 months, 12 months, years 1-10.
Change in hypertension from pre-procedure to 10 years using medication dosages
Change of hypertension status by comparing change in dosage (mg) of hypertension medications from baseline.
Time frame: Baseline, 3 months, 6 months, 9 months, 12 months, years 1-10.
Change in medication dosage to determine change in diabetes status from pre-procedure to 10 years
Change of diabetes status by comparing change in dosage (mg) of diabetes medications from baseline to 10 years.
Time frame: Baseline, 3 months, 6 months, 9 months, 12 months, years 1-10.
Change percent value of HgA1c to determine change in diabetes status from pre-procedure to 10 years
Change of HgA1c (%) by comparing lab values from baseline through 10 years.
Time frame: Baseline, 3 months, 6 months, 9 months, 12 months, years 1-10.
Change in total cholesterol lab values (mg/dL) from pre-procedure to 10 years
Change in total cholesterol measurements by comparing followup lab values (mg/dL) to baseline.
Time frame: Baseline, 3 months, 6 months, 9 months, 12 months, years 1-10.
Change in low density lipoprotein (LDL) lab values (mg/dL) from pre-procedure to 10 years
Change in LDL measurements by comparing followup lab values (mg/dL) to baseline.
Time frame: Baseline, 3 months, 6 months, 9 months, 12 months, years 1-10.
Change in high density lipoprotein (HDL) lab values (mg/dL) from pre-procedure to 10 years
Change in HDL measurements by comparing followup lab values (mg/dL) to baseline.
Time frame: Baseline, 3 months, 6 months, 9 months, 12 months, years 1-10.
Change in medication dosage (mg) to determine change in total cholesterol (mg/dL) from pre-procedure to 10 years
Change in total cholesterol measurements by comparing change in dosage of cholesterol medications (mg) from baseline to 10 years.
Time frame: Baseline, 3 months, 6 months, 9 months, 12 months, years 1-10.
Change in medication dosage (mg) to determine change in High Density Lipoprotein (HDL) (mg/dL) from pre-procedure to 10 years
Change in HDL measurements by comparing change in dosage of cholesterol medications (mg) from baseline to 10 years.
Time frame: Baseline, 3 months, 6 months, 9 months, 12 months, years 1-10.
Change in medication dosage (mg) to determine change in Low Density Lipoprotein (LDL) (mg/dL) from pre-procedure to 10 years
Change in LDL measurements by comparing change in dosage of cholesterol medications (mg) from baseline to 10 years.
Time frame: Baseline, 3 months, 6 months, 9 months, 12 months, years 1-10.
Change in rate of adverse events from procedure to 10 years
Change in rate of adverse events post-procedure through 10 years
Time frame: Procedure, 1 month, 3 months, 6 months, 9 months, 12 months, years 1-10.
Change in comorbidity medication dosages from baseline to 10 years
Change of dosage of comorbidity medications compared to baseline
Time frame: Baseline, 1 month, 3 months, 6 months, 9 months, 12 months, years 1-10.
Change in gastric motility from baseline to 10 years
Gastric emptying breath test
Time frame: Baseline, 1 month, 3 months, 6 months, 9 months, 12 months, years 1-10.
Change in PYY gut hormones from baseline to 10 years
PYY lab values will be compared to baseline
Time frame: Baseline, 1 month, 3 months, 6 months, 9 months, 12 months, years 1-10.
Change in GLP1 gut hormones from baseline to 10 years
GLP1 lab values will be compared to baseline
Time frame: Baseline, 1 month, 3 months, 6 months, 9 months, 12 months, years 1-10.
Change in ghrelin hormones from baseline to 10 years
Ghrelin lab values will be compared to baseline
Time frame: Baseline, 1 month, 3 months, 6 months, 9 months, 12 months, years 1-10.
Cost comparison of procedural costs associated with bariatric endoscopic vs. surgical procedures from baseline to 10 years
Cost-effectiveness analysis of procedure costs from admission to discharge for endoscopic vs. surgical bariatric procedures
Time frame: Pre-intervention/procedure/surgery, during the procedure/surgery, immediately after the intervention/procedure/surgery, up to 3 months after the intervention/procedure/surgery
Plan to share: Undecided — Depending on the range of data and publication status, the PI will consider de-identified data sharing with a data transfer agreement in place after discussion of parameters and study design.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Christopher C. Thompson, MD, MSc